Abcely is a health biotechnology start-up specializing in the development of a completely new class of therapeutic molecules, orally-active class A immunoglobulins. These molecules have a tropism of distribution and action in all the mucous membranes of the body. (digestive, respiratory, urogenital tract and associated glandular systems such as the breast or prostate).
The drug candidate developed by Abcely, ABC-101, is the first class A, orally active monoclonal antibody directed against a tumor marker that is extremely well validated in oncology: CEA (Carcino-Embryo Antigen). CEA was chosen as a target because many digestive and mucosal cancers (lungs, urogenital tract and associated glands) overexpress this marker during cancerous transformation.
Abcely is also involved in the R&D of IgA applied to the field of endometriosis treatment, a very disabling pathology affecting approximately 10% of women.

Abcely’s mission is to develop new innovative medical and pharmaceutical technologies in the field of the treatment of mucosal cancers, thus offering patients in therapeutic impasse a new solution based on a brand-new concept of immunotherapy in cancerology. The unique concept developed by Abcely is based on the use of a new class of orally active therapeutic molecules (IgA). Abcely is involved in all phases of development, from the identification of compounds of biological origin as potential active ingredients to the demonstration of their activity in the human clinic. Abcely’ positioning in the competitive landscape is unique since no other orally-active IgA is being developed in oncology or any other indication.

–  Therapeutic areas: oncology, immotherapy, endometriosis, inflammation

–  Based in: Nantes (FRANCE)

–  Employees: 1-10

– Created in: 2022

3Biotech provides continuously innovative solutions to challenge, support and accelerate the manufacturing of safe drug candidates.
They are your colleagues, partner for the Chemistry, Manufacturing and Control (CMC) to succeed in your project and mission to create a new future and impact patient outcomes.
Three Pillars: Safety, Efficacy and Manufacturing are their drivers to secure all steps from the research to the first in human stage with the most innovative project strategy and plan to execution.
They have implemented an organization to provide you with the best support on the field.

Their solutions to succeed:
– Challenging, risk assessment and, crash test (Due diligence, Gap analysis, Definition of the QTPP …)
– Lead optimization and selection,
– Translational Research
– Define and execute a “Chemistry Manufacturing and Control” strategy all along the drug development.
– Identify the most appropriate technological solutions (cell lines, manufacturing processes, analytical methods, …)
– Select, worldwide, appropriate CRO / CDMOs none GMP and GMP grade
– Define the most cost-effective process development
– Lead and coordinate all stakeholders and ensure timelines, quality and cost program and monitor the production of clinical batches,
– Pilot Clinical supply
– Support in writing IMPD and IND
– A unique global project management

–  Therapeutic areas: Oncology, Cardiology, Neurology, Psychiatry, Endocrinology, Rheumatology, Infectious Diseases, Gastroenterology, Pulmonology

–  Based in: Paris (FRANCE)

–  Employees: 1-10

– Created in: 2014